

Antidepressant Drugs Market - 2022-2031

<https://marketpublishers.com/r/AA6A8F02BDF7EN.html>

Date: November 2025

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: AA6A8F02BDF7EN

Abstracts

The Antidepressant Drugs Market was valued at US\$ 14.3 billion in 2022 and is anticipated to reach US\$ 20.6 billion by 2031, at a CAGR of 0.0556 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Antidepressant Drugs Market.

This report delivers a comprehensive overview of the Antidepressant Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antidepressant Drugs Market. The Antidepressant Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

Antidepressant Drugs Market Scope:

By Drug Class

Monoamine Oxidase Inhibitors

Norepinephrine-Dopamine Reuptake Inhibitor

Serotonin-Norepinephrine Reuptake Inhibitors

Selective Serotonin Reuptake Inhibitors

Tricyclic Antidepressants

By Depression Disorder

Major Depressive Disorder

Obsessive-Compulsive Disorder

Generalized Anxiety Disorder

Panic Disorder

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

Key Players

Eli Lilly and Company

GlaxoSmithKline Plc.

LGM Pharma LLC

Apotex Inc.

Zhejiang Huahai Pharmaceutical Co. Ltd.

AstraZeneca Plc.

Takeda Pharmaceutical Co. Ltd

Pfizer Inc.

Aurobindo Pharma Limited

Merck KGaA

Major Highlights

This report delivers a comprehensive overview of the Antidepressant Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antidepressant Drugs Market. The Antidepressant Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering

in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Drug Class
- 3.2. Snippet by Depression Disorder
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Research and Developments for Antidepressant Drugs
 - 4.1.1.2. Increasing Approvals for Antidepressant Drugs
 - 4.1.2. Restraints
 - 4.1.2.1. Side Effects Associated with Treatment Drugs
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
- 5.5. DMI Opinion

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19

- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. BY DRUG CLASS

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Monoamine Oxidase Inhibitors
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 7.2.3. Isocarboxazid
 - 7.2.4. Phenzelzine
 - 7.2.5. Selegiline
 - 7.2.6. Tranylcypromine
- 7.3. Norepinephrine-Dopamine Reuptake Inhibitor
 - 7.3.1. Amineptine
 - 7.3.2. Bupropion
 - 7.3.3. Desoxypipradrol
 - 7.3.4. Dexmethylphenidate
 - 7.3.5. Difemetorex
- 7.4. Serotonin-Norepinephrine Reuptake Inhibitors
 - 7.4.1. Desvenlafaxine
 - 7.4.2. Duloxetine
 - 7.4.3. Levomilnacipran
 - 7.4.4. Milnacipran
 - 7.4.5. Venlafaxine
- 7.5. Selective Serotonin Reuptake Inhibitors
 - 7.5.1. Citalopram
 - 7.5.2. Escitalopram
 - 7.5.3. Fluoxetine
 - 7.5.4. Paroxetine
 - 7.5.5. Sertraline
- 7.6. Tricyclic Antidepressants

- 7.6.1. Amitriptyline
- 7.6.2. Amoxapine
- 7.6.3. Desipramine
- 7.6.4. Doxepin
- 7.6.5. Imipramine
- 7.6.6. Nortriptyline
- 7.6.7. Others

8. BY DEPRESSION DISORDER

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
 - 8.1.2. Market Attractiveness Index, By Depression Disorder
- 8.2. Major Depressive Disorder
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Obsessive-Compulsive Disorder
- 8.4. Generalized Anxiety Disorder
- 8.5. Panic Disorder
- 8.6. Others

9. BY DISTRIBUTION CHANNEL

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacy
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacy
- 9.4. Online Pharmacy
- 9.5. Others

10. BY REGION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America

- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.2.6.1. U.S.
 - 10.2.6.2. Canada
 - 10.2.6.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics
 - 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
 - 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.3.6.1. Germany
 - 10.3.6.2. U.K.
 - 10.3.6.3. France
 - 10.3.6.4. Italy
 - 10.3.6.5. Spain
 - 10.3.6.6. Rest of Europe
- 10.4. South America
 - 10.4.1. Introduction
 - 10.4.2. Key Region-Specific Dynamics
 - 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
 - 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.4.6.1. Brazil
 - 10.4.6.2. Argentina
 - 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
 - 10.5.1. Introduction
 - 10.5.2. Key Region-Specific Dynamics
 - 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
 - 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
 - 10.6.1. Introduction
 - 10.6.2. Key Region-Specific Dynamics
 - 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
 - 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE

- 11.1. Competitive Scenario
- 11.2. Product Benchmarking
- 11.3. Company Share Analysis
- 11.4. Key Developments and Strategies

12. COMPANY PROFILES

- 12.1. Eli Lilly and Company*
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio and Description
 - 12.1.3. Financial Overview
 - 12.1.4. Key Developments
- 12.2. GlaxoSmithKline Plc.
- 12.3. LGM Pharma LLC
- 12.4. Apotex Inc.
- 12.5. Zhejiang Huahai Pharmaceutical Co. Ltd.
- 12.6. AstraZeneca Plc.
- 12.7. Takeda Pharmaceutical Co. Ltd
- 12.8. Pfizer Inc.
- 12.9. Aurobindo Pharma Limited
- 12.10. Merck KGaA (*LIST NOT EXHAUSTIVE)

13. APPENDIX

- 13.1. About Us and Services

13.2. Contact Us

I would like to order

Product name: Antidepressant Drugs Market - 2022-2031

Product link: <https://marketpublishers.com/r/AA6A8F02BDF7EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA6A8F02BDF7EN.html>